BC
DNLI icon

Bridgefront Capital’s Denali Therapeutics DNLI Stock Holding History

Bridgefront Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,084
Closed -$178K – 662
2025
Q1 		$178K Buy
+13,084
New +$251K 0.05% 540

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgefront Capital's DNLI Position: Q2 2025 in Review

Bridgefront Capital sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 13,084 shares — an estimated $178K sold.

Bridgefront Capital first reported a position in DNLI in Q1 2025 and held it in 1 quarter. The position peaked at $178K in Q1 2025. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Bridgefront Capital reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 13,084 Denali Therapeutics shares in Q2 2025, an estimated $178K.
  • Bridgefront Capital first reported a position in Denali Therapeutics in Q1 2025 and held it in 1 quarter.
  • Bridgefront Capital's Denali Therapeutics position peaked at $178K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.